Galapagos NV
29.90%
20,981,010
1421876
36315X101
Jan 6, 2025
Jan 10, 2025, 03:46 PM
Reporting Persons (2)
This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | CO | 29.90% | 20,981,010 | 0 | 20,981,010 |
| Gilead Therapeutics A1 Unlimited Company | CO | 29.90% | 20,981,010 | 0 | 20,981,010 |
Disclosure Items (7)
Ordinary Shares, no par value
Galapagos NV
Generaal De Wittelaan L11 A3, Mechelen, C9, 2800
Item 2 of the Schedule 13D is hereby amended and replaced with the following: This Schedule 13D is being filed by the Reporting Persons. The address of the principal business office of Gilead is 333 Lakeside Drive, Foster City, California, 94404. The address of the principal business office of A1 is 70 Sir John Rogerson's Quay, Dublin 2, Ireland. The principal business of the Reporting Persons is to develop and commercialize innovative medicines in areas of unmet medical need and engage in any other activity or business which may be lawfully carried on by a corporation organized under such entity's jurisdiction of organization. The name, residence or business address, present principal occupation and citizenship of each director, executive officer and controlling person of Gilead and A1 is attached hereto as Exhibit 99.3.
See (a).
See (a).
During the last five years, neither the Reporting Persons, nor, to the knowledge of the Reporting Persons, any of the persons listed on Exhibit 99.3 hereto was a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
See (a).
No amendment to this Item is being made.
No amendment to this Item is being made.
No amendment to this Item is being made.
Except as set forth in Item 4 of this Schedule 13D/A or as previously disclosed in the Schedule 13D, neither the Reporting Persons nor, to the best knowledge of the Reporting Persons, any person named in Item 2 of this Schedule 13D/A has effected any transaction in Ordinary Shares during the past 60 days.
No person other than the Reporting Persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities beneficially owned by the Reporting Persons identified in this Item 5.
Not applicable.
Item 6 is hereby amended and supplemented with the addition of the following: The information set forth above in Item 4 above with respect to the Separation Agreement is incorporated herein by reference.
Item 7 is hereby amended and supplemented with the addition of the following: 99.3 Directors and Executive Officers of Reporting Persons. 99.4 Separation Agreement, dated January 7, 2025, by and between Galapagos NV, Gilead Therapeutics A1 Unlimited Company and Gilead Sciences, Inc.